Printer Friendly

Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board.

- Dr. Roscoe M. Moore, Jr. to join Board -

PRINCETON, N.J. and SAN DIEGO, June 4 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the addition of Roscoe Moore Jr., D.V.M., Ph.D., D.Sc. to their Scientific Advisory Board.

"We expect Dr. Moore to contribute significantly to our already robust Scientific Advisory Board. His expertise across all areas of public health and infectious diseases will be a tremendous asset to Tobira Therapeutics," said James Sapirstein, CEO.

Dr. Moore, President, PH RockWood Corporation, Rockville, Maryland and Pretoria, South Africa, is the Former Assistant United States Surgeon General and Rear Admiral, United States Public Health Service (Retired). Until his retirement Dr. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for development support within the Office of the Secretary, Health and Human Services (HHS). Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control (CDC) and Prevention. He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.

Dr. Moore received his undergraduate and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Honorary Doctor of Science degree in recognition of his distinguished public health career by Tuskegee University.

Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.
 Contact:
 Tobira Therapeutics Inc.
 Antoinette Bobbitt
 abobbitt@tobiratherapeutics.com
 Tel: 609-897-1102
 http://www.tobiratherapeutics.com/



CONTACT: Antoinette Bobbitt of Tobira Therapeutics Inc., +1-609-897-1102, abobbitt@tobiratherapeutics.com

Web Site: http://www.tobiratherapeutics.com/
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 4, 2009
Words:486
Previous Article:AT&T Expands Its Maine Wireless Network.
Next Article:Ten Ashford University Online Faculty Receive NISOD 2009 Excellence Awards.


Related Articles
Tobira Therapeutics Inc. Completes $31 Million Series A Financing and Names Management Team.
Tobira Therapeutics Inc. Announces Senior Management Team.
Tobira Therapeutics Inc. Receives US Patent for TBR-652.
Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum.
Tobira Therapeutics Inc. Initiates Proof of Concept Study with TAK-652 for the Treatment of HIV.
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV.
Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV.
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters